Curaleaf Holdings
Market Cap
CA$3.1b
Last Updated
2020/03/31 04:10 UTC
Data Sources
Company Financials +
Executive Summary
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential and slightly overvalued.
Similar Companies
Share Price & News
How has Curaleaf Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CURA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
5.7%
CURA
5.9%
CA Pharmaceuticals
3.7%
CA Market
1 Year Return
-55.8%
CURA
-74.8%
CA Pharmaceuticals
-23.7%
CA Market
Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned -74.3% over the past year.
Return vs Market: CURA underperformed the Canadian Market which returned -24.5% over the past year.
Shareholder returns
| CURA | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.7% | 5.9% | 3.7% |
| 30 Day | -17.1% | -19.2% | -19.7% |
| 90 Day | -27.9% | -35.1% | -24.3% |
| 1 Year | -55.8%-55.8% | -74.8%-74.8% | -21.2%-23.7% |
| 3 Year | n/a | -16.8%-17.4% | -13.3%-21.4% |
| 5 Year | n/a | 195.5%195.5% | -0.8%-15.5% |
Price Volatility Vs. Market
How volatile is Curaleaf Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
These Analysts Think Curaleaf Holdings, Inc.'s (CSE:CURA) Earnings Are Under Threat2 weeks ago | Simply Wall St
What Kind Of Investor Owns Most Of Curaleaf Holdings, Inc. (CSE:CURA)?1 month ago | Simply Wall St
Introducing Curaleaf Holdings (CSE:CURA), The Stock That Dropped 17% In The Last YearValuation
Is Curaleaf Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CURA (CA$5.9) is trading below our estimate of fair value (CA$43.95)
Significantly Below Fair Value: CURA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CURA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: CURA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CURA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CURA is overvalued based on its PB Ratio (4.8x) compared to the CA Pharmaceuticals industry average (0.9x).
Next Steps
Future Growth
How is Curaleaf Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
69.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CURA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: CURA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CURA's is expected to become profitable in the next 3 years.
Revenue vs Market: CURA's revenue (31.4% per year) is forecast to grow faster than the Canadian market (3.8% per year).
High Growth Revenue: CURA's revenue (31.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CURA's Return on Equity is forecast to be low in 3 years time (1.1%).
Next Steps
Past Performance
How has Curaleaf Holdings performed over the past 5 years?
-19.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CURA is currently unprofitable.
Growing Profit Margin: CURA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CURA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-9.9%).
Return on Equity
High ROE: CURA has a negative Return on Equity (-17.31%), as it is currently unprofitable.
Next Steps
Financial Health
How is Curaleaf Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CURA's short term assets ($149.5M) exceed its short term liabilities ($106.3M).
Long Term Liabilities: CURA's short term assets ($149.5M) do not cover its long term liabilities ($227.2M).
Debt to Equity History and Analysis
Debt Level: CURA's debt to equity ratio (26%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CURA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: CURA has a high level of physical assets or inventory.
Debt Coverage by Assets: CURA's debt is covered by short term assets (assets are 1.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CURA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CURA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CURA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CURA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CURA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.3yrs
Average management tenure
CEO
Joseph Lusardi (45yo)
4s
Tenure
US$2,231,000
Compensation
Mr. Joseph Lusardi serves as a Director of Curaleaf Holdings, Inc. since March 2016 and was its President until January, 2019. Mr. Lusardi has been the Chief Executive Officer of Curaleaf Holdings, Inc. si ...
CEO Compensation Analysis
Compensation vs Market: Joseph's total compensation ($USD2.23M) is about average for companies of similar size in the Canadian market ($USD2.56M).
Compensation vs Earnings: Joseph's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$1.50m | 23.61% $733.3m | |
| CEO & Director | 4yrs | US$2.23m | 0.80% $24.7m | |
| President | 0.25yr | no data | no data | |
| Chief Financial Officer | no data | no data | no data | |
| COO & Treasurer | no data | no data | no data | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| Executive VP of Business Development & Interim General Counsel | 0.17yr | no data | no data | |
| Vice President of Corporate Communications | 0.25yr | no data | no data | |
| Senior Vice President of Sales | no data | no data | no data | |
| Chief Marketing Officer | no data | no data | no data |
0.3yrs
Average Tenure
51yo
Average Age
Experienced Management: CURA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | US$1.50m | 23.61% $733.3m | |
| CEO & Director | 4yrs | US$2.23m | 0.80% $24.7m | |
| Independent Director | 1.42yrs | US$12.50k | 0.083% $2.6m | |
| Independent Director | 1.42yrs | US$12.50k | 0.0033% $101.2k | |
| Chairman of the Medical Advisory Board | no data | US$81.95k | no data | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Member of the Medical Advisory Board | no data | no data | no data | |
| Director | no data | no data | no data |
1.4yrs
Average Tenure
58yo
Average Age
Experienced Board: CURA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.
Top Shareholders
Company Information
Curaleaf Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Curaleaf Holdings, Inc.
- Ticker: CURA
- Exchange: CNSX
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$3.106b
- Shares outstanding: 526.40m
- Website: https://www.curaleaf.com
Number of Employees
Location
- Curaleaf Holdings, Inc.
- 301 Edgewater Place
- Suite 405
- Wakefield
- Massachusetts
- 1880
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CURA | CNSX (Canadian National Stock Exchange) | Yes | Subordinated Voting Shares | CA | CAD | Oct 2018 |
| CURL.F | OTCPK (Pink Sheets LLC) | Yes | Subordinated Voting Shares | US | USD | Oct 2018 |
Biography
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It cultivates, processes, markets, and/or dispenses a range of cannabis products, such as vape oils and concentrates; flower, pre-rolls, and flower pods; topical lotions; capsules and tinctures; mints and lozenges; and edibles. The company also provides hemp-based CBD products. As of January 29, 2020, it operated 52 dispensaries, 14 cultivation sites, and 14 processing sites in 12 states. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/31 04:10 |
| End of Day Share Price | 2020/03/30 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.